



## **Ophthalmic Devices Panel for the Medical Devices Advisory Committee and the Risk Communication Advisory committee (RCAC)**

**Hilton Washington, Gaithersburg  
March 17, 2017**

**Discuss and make recommendation regarding the potential risks of misuse of peroxide-based  
contact lens products**

**Panel Chairperson**  
Jayne S. Weiss, M.D.

**Designated Federal Officer**  
Aden S. Asefa, M.P.H.

- 07:30 a.m. Call to Order  
Panel Introductions  
Conflict of Interest  
FDA Introductory Remarks**
- 07:55 a.m. FDA Presentations  
Contact lens regulations: Overview/History of contact lens care products  
Clinical Presentation about the misuse of peroxide-based care products  
Post Market Surveillance  
Patient Perspective Initiative**
- 08:55 a.m. Questions to FDA**
- 09:05 a.m. Dr. Ruth Day, Ph.D. – *Labeling Comprehension: Effects of Standard vs. Enhanced Displays* [25’/5’ questions]**
- 09:35 a.m. Rollin J. “Terry” Fairbanks, M.D. - *Human Factors Engineering: The Science Behind Designing for Human Use* [25’/5’]**
- 10:05 a.m. Break**
- Manufacturers of Hydrogen Peroxide Care Products**
- 10:15 a.m. Alcon - *The Realities of Hydrogen Peroxide Lens Care Use & Misuse in Today’s Marketplace* [15’/5’]**
- 10:35 a.m. CooperVision – *The Vantage Point of CooperVision’s Peroxide System* [15’/5’]**
- Presentations from Professional Organizations**
- 10:55 a.m. Institute for Safe Medication Practices (ISMP) – *Labeling and Packaging Improvements needed for Peroxide-based Contact Lens Cleaning Agents.* [10’/5’]**
- 11:10 a.m. American Academy of Optometry (AAO) – *Hydrogen Peroxide Contact Lens Care Systems: A Collaboration for Success* [10’/5’]**



<b>11:25</b>	<b>a.m.</b>	<b>American Optometric Association (AOA) – <i>Perspectives and Recommendations on Peroxide-based Contact Lens Products from the American Optometric Association</i> [10’/5]</b>
<b>11:40</b>	<b>a.m.</b>	<b>Contact Lens Association of Ophthalmologists (CLAO) – <i>Medical Perspectives on Peroxide-Based Contact Lens Products</i> [10’/5’]</b>
<b>11:55</b>	<b>a.m.</b>	<b>Lunch</b>
<b>01:00</b>	<b>p.m.</b>	<b>Open Public Hearing*</b>
<b>02:00</b>	<b>p.m.</b>	<b>Panel Deliberations/FDA Questions</b>
<b>02:30</b>	<b>p.m.</b>	<b>Break</b>
<b>02:40</b>	<b>p.m.</b>	<b>FDA Questions Cont.</b>
<b>04:00</b>	<b>p.m.</b>	<b>Adjourn</b>

\* **Open Public Hearing** – Interested persons may present data, information, or views, orally or in writing, on the issue pending before the panel. Scheduled speakers who have requested time to address the panel will speak at this time. After they have spoken, the Chair may ask them to remain if the panel wishes to question them. Then the Chair will recognize unscheduled speakers as time allows. Only the panel may question speakers during the open public hearing.